Development of bio-similar to exendin-4, a major drug for type 2 diabetes
The hallmark of diabetes mellitus is hyperglycemia resulting from impaired carbohydrate metabolism
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
The hallmark of diabetes mellitus is hyperglycemia resulting from impaired carbohydrate metabolism
Biologics differ from small molecule drugs in that the structure of the
A current global trend in the development of biomedical and pharmaceutical chemistry
Biosimilars are increasingly being developed by many companies and used as therapeutics
During 2016 the UP and UPC will come into force in Europe
Objective: The aim of this study was to assess the bioequivalence of
Herbal medicines, also known as botanical medicines or phytomedicines, refer to the
To support a claim of Biosimilarity, the EMA and FDA are interested
The model for bringing a biosimilar drug to market is evolving; the
Biosimilars are entering the landscape as patents for major branded large molecule
Biocides are an essential part of infection control practices and aid in
Drug safety is a very basic and fundamental concept in medical practice
This study utilized safety, pharmacodynamic and pharmacokinetic data to compare the biosimilarity
Expression of recombinant proteins in the milk of transgenic dairy goats has
PEGylation is commonly used to generate long-acting biologics (Biobetters). However, there
Streptokinase, a 414 amino acid polypeptidewithmolecularweightof 47kDa, is a potent activator of
As more and more blockbuster biologics loose patent protection, hundreds of biosimilar
In Europe biosimilars are governed by the statutory provisions applicable for generic
SPC squatting and SPCs for biologics are a hot topic in Europe
Biosimilars in the US are still in their infancy with only one
Biopharmaceuticals represent a very promising option for treating the most challenging diseases
Biotherapeutic products are the fastest growing medicines in the pharmaceutical market. Here
Biologics are products manufactured from living matter or manufactured in living cells
Biosimilars are highly-similar versions of biological drugs (biologics) approved for the
The lecture will cover The presentation will cover assessing the promise and
For authors and organisers
Find the right journal for your paper and submit your manuscript.